Pacira Pharma (PCRX): Symphony Health Data Accelerates In November - Wedbush

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) after Symphony Health data for EXPAREL estimated sales per day in November increased 11.2% above October. This is above Bupivacaine +8% and Marcaine -2%.

Total November EXPAREL sales tracked within about -3% of consensus but Symphony Health sales and volume estimates for November were more than $22 million (WAC$) and more than 71 thousand pack units.

No change to the price target of $89.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $31.90 yesterday.

You May Also Be Interested In

• Pacira BioSciences (PCRX) August 20 and 25 put spreader active
• Boston Scientific (BSX) PT Raised to $80 at BTIG
• Boston Scientific (BSX) PT Raised to $83 at Stifel